FDA Launches Compounding Quality Center of Excellence Discussion Series for Outsourcing Facilities

Outsourcing facilities operating under 21 CFR Part 211 now have a structured FDA channel to benchmark cGMP practices, address drug shortage pressures, and build peer networks, through the Compounding Quality Center of Excellence, which has opened two recurring discussion series and a cross-sector advisory group to industry participants.

The Center operates two distinct tracks. The New Outsourcing Facility Discussion Series targets recently registered facilities, their management, consultants, and compounders evaluating outsourcing facility registration. Sessions run several times per year and pair newer entrants with more experienced facilities to accelerate baseline compliance knowledge. The Quality Discussion Series is aimed at facilities with an established quality posture, covering quality culture, best practices, and cGMP requirements; purchasers of compounded drugs and pharmacy organizations are also listed as intended participants, widening the peer reference pool beyond manufacturers alone.

For QA directors, the practical value sits in the peer-exchange mechanism. Both series are designed to surface common compliance challenges and shared solutions across the outsourcing facility sector, a function that maps directly to the continuous improvement expectations embedded in ICH Q10 pharmaceutical quality systems. Facilities that have historically relied on internal benchmarking or third-party consultants gain a direct, FDA-facilitated forum for cross-industry calibration.

A third engagement pathway, the Cross-Sector Stakeholder Group, operates as a smaller expert cohort addressing systemic issues including drug shortages and longer-term industry trajectory. Participation in this group is not open-enrollment in the same manner as the discussion series; the source material positions it as a select group of industry experts, suggesting a nomination or application dynamic, though the FDA has not published explicit eligibility criteria in the available documentation.

The Center's framing around patient safety as a shared industry responsibility signals that FDA views outsourcing facility quality performance as a collective, not solely a firm-level, compliance obligation, a posture consistent with the agency's increased scrutiny of the compounding sector following high-profile sterility failures in prior years.

Facilities evaluating participation should note that email registration for Center updates is the stated entry point, with session frequency confirmed as several times per year for both discussion tracks.

Source: U.S. Food and Drug Administration via FDA.gov Drugs RSS Feed, June 9, 2026.